Regarding HF treatments, 85.5% were taking a renin‐angiotensin system inhibitor, mainly angiotensin‐converting enzyme inhibitors, 79.7% beta‐blockers, and 51.4% mineralocorticoid receptor antagonists. This evidence concerns the gene NR3C2 and hydrops fetalis.